| Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. | |
| | |
MedLine Citation:
|
PMID: 14634033 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The disposition of digoxin and the influence of the organic anion transporting polypeptide (Oatp)2 inhibitor rifampicin and the P-glycoprotein (P-gp) inhibitor quinidine on its hepatic disposition were examined in the isolated perfused rat liver. Livers from groups of rats were perfused in a recirculatory manner after a bolus dose of digoxin (10 microg), a dual substrate for Oatp2 and P-gp as well as CYP3A. Perfusions of digoxin were also examined in groups of rats in the presence of the inhibitors: rifampicin (100 microM) or quinidine (10 microM). In all experiments, perfusate samples were collected for 60 min. Digoxin and its primary metabolite were determined in perfusate and liver by liquid chromatography/mass spectrometry. The area under the curve (AUC) from 0 to 60 min was determined. The AUC +/- S.D. of digoxin was increased from control (3880 +/- 210 nM x min) by rifampicin (5200 +/- 240 nM x min; p < 0.01) and decreased by quinidine (3220 +/- 340 nM x min; P < 0.05). It is concluded that rifampicin limits the hepatic entrance of digoxin and reduced the hepatic exposure of digoxin to CYP3A by inhibiting the basolateral Oatp2 uptake transport, whereas quinidine increased the hepatic exposure of digoxin to CYP3A by inhibiting the canalicular P-gp transport. These data emphasize the importance of uptake and efflux transporters on hepatic drug metabolism. |
| | |
Authors:
|
Yvonne Y Lau; Chi-Yuan Wu; Hideaki Okochi; Leslie Z Benet |
Related Documents
:
|
18143 - The mechanism of inhibition by acidosis of gluconeogenesis from lactate in rat liver. 21452373 - Black tea prevents high fat diet-induced non-alcoholic steatohepatitis. 8354343 - Metformin and brown adipose tissue thermogenetic activity in genetically obese zucker r... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. Date: 2003-11-21 |
Journal Detail:
|
Title: The Journal of pharmacology and experimental therapeutics Volume: 308 ISSN: 0022-3565 ISO Abbreviation: J. Pharmacol. Exp. Ther. Publication Date: 2004 Mar |
Date Detail:
|
Created Date: 2004-02-26 Completed Date: 2004-04-06 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0376362 Medline TA: J Pharmacol Exp Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 1040-5 Citation Subset: IM |
Affiliation:
|
Department of Biopharmaceutical Sciences, University of California, San Francisco, San Francisco, CA 9414-0446, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Biological Transport Digoxin / metabolism* Liver / drug effects*, metabolism Male Membrane Transport Proteins Perfusion Quinidine / pharmacokinetics Rats Rats, Sprague-Dawley Rifampin / pharmacokinetics |
| Grant Support | |
ID/Acronym/Agency:
|
GM-61390/GM/NIGMS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Membrane Transport Proteins; 13292-46-1/Rifampin; 20830-75-5/Digoxin; 56-54-2/Quinidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and ...
Next Document: Acute cardiovascular effects of sibutramine in conscious rats.